CORDIS
EU research results

CORDIS

English EN

Personalized And/Or Generalized Integrated Biomaterial Risk Assessment

Project information

Grant agreement ID: 760921

Status

Ongoing project

  • Start date

    1 January 2018

  • End date

    31 December 2021

Funded under:

H2020-EU.2.1.3.

  • Overall budget:

    € 7 992 471

  • EU contribution

    € 7 992 471

Coordinated by:

STEINBEIS 2I GMBH

Germany

Objective

PANBioRA aims at providing a comprehensive solution for the time- and cost-effective risk assessment of i) new biomaterials under health or disease states or ii) a given biomaterial for each patient in a personalized manner. It will standardize the evaluation of biomaterials and open the venue for pre-implantation, personalized diagnostics for biomaterial based applications.
PANBioRA will provide a modular platform to assess risks at different aspects and length scales. This comprises antibody response, cytotoxicity/genotoxicity at cell level, systemic and local effects at tissue and connected tissues (organ-on-a-chip) level. Moreover, physicochemical and biomechanical characterisation as well as predictive modelling at systems level will complement the system. This will be achieved by connecting testing modules in a structure supported by web-based modelling and risk radar tools together with a biomechanical testing system.
The platform will incorporate standardized protocols yielding significantly more information than the current methods for biomaterial risk assessment. Its accuracy will be demonstrated using known reference materials and validated in a pre-clinical setting.
PANBioRA will for the first time, predict the patient specific response to a given biomaterial before its implantation. This measure will allow for the selection of the best suitable material, minimizing side effects and improving health outcomes.
It will also accelerate the process of validation of the biocompatibility of new devices by providing an automated, comprehensive process for the parallel assessment of risks at different scales aiding new biomaterial discovery and commercialisation.
Altogether, PANBioRA will lead to a substantial economic impact due to a reduction of the amount of tests, decrease in healthcare costs due to complications. It will provide the necessary tools proper risk management related to biomaterials.

Coordinator

STEINBEIS 2I GMBH

Address

Kienestrasse 35
70174 Stuttgart

Germany

Activity type

Private for-profit entities (excluding Higher or Secondary Education Establishments)

EU Contribution

€ 499 625

Participants (16)

DOLMEN DESIGN AND INNOVATION LIMITED

Ireland

EU Contribution

€ 319 375

BIODEVICE SYSTEMS SRO

Czechia

EU Contribution

€ 296 875

PROTOBIOS OU

Estonia

EU Contribution

€ 400 000

ELVESYS

France

EU Contribution

€ 406 875

STREINBEIS ADVANCED RISK TECHNOLOGIES INSTITUTE DOO KRAGUJEVAC

Serbia

EU Contribution

€ 310 000

STEINBEIS ADVANCED RISK TECHNOLOGIES GMBH

Germany

EU Contribution

€ 587 500

COMMISSARIAT A L ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES

France

EU Contribution

€ 754 261,25

PRO-ACTIVE

Belgium

EU Contribution

€ 177 812,50

AALTO KORKEAKOULUSAATIO SR

Finland

EU Contribution

€ 401 990

TURGUT OZAL EDUCATION SHA

Albania

EU Contribution

€ 321 375

THE UNIVERSITY OF NOTTINGHAM

United Kingdom

EU Contribution

€ 708 756

AGENCIA ESTATAL CONSEJO SUPERIOR DEINVESTIGACIONES CIENTIFICAS

Spain

EU Contribution

€ 554 763,75

DUBLIN CITY UNIVERSITY

Ireland

EU Contribution

€ 392 962,50

INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE

France

EU Contribution

€ 499 662,50

CENTRE HOSPITALIER UNIVERSITAIRE DE LIEGE

Belgium

EU Contribution

€ 399 637,50

PROTIP MEDICAL

France

EU Contribution

€ 961 000

Project information

Grant agreement ID: 760921

Status

Ongoing project

  • Start date

    1 January 2018

  • End date

    31 December 2021

Funded under:

H2020-EU.2.1.3.

  • Overall budget:

    € 7 992 471

  • EU contribution

    € 7 992 471

Coordinated by:

STEINBEIS 2I GMBH

Germany